VERV
VERVE THERAPEUTICS INC
No data for this timeframe.
Vol
Inst. Holders1 funds
Inst. Value$1.1M
Inst. Activity0 buys / 11 sells
Recent Activity
Inst.
BARCLAYS PLC — TRIM
222,919 shares ($1.1M)
Inst.
BlackRock, Inc. — EXIT
0 shares ($0.00)
Analyst Ratings
2Strong Buy
4Buy
8Hold
0Sell
0Strong Sell
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BARCLAYS PLC | $1.1M | TRIM |
1 institutional holders with $1.1M total value (222,919 shares) as of 2025-Q3. Top holders: BARCLAYS. Net selling activity: 11 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q3
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BARCLAYS PLC | 222,919 | $1.1M | 100.0% | TRIM -26.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BARCLAYS PLC | TRIM | 301,599 | 222,919 | -26.1% | $1.1M | 2025-Q3 |
| BlackRock, Inc. | EXIT | 7,356,721 | 0 | -100.0% | $0.00 | 2025-Q3 |
| STATE STREET CORP | EXIT | 2,626,859 | 0 | -100.0% | $0.00 | 2025-Q3 |
| UBS Group AG | EXIT | 1,870,522 | 0 | -100.0% | $0.00 | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 1,047,600 | 0 | -100.0% | $0.00 | 2025-Q3 |
| Nuveen, LLC | EXIT | 1,611,913 | 0 | -100.0% | $0.00 | 2025-Q3 |
| Hudson Bay Capital Management LP | EXIT | 1,747,598 | 0 | -100.0% | $0.00 | 2025-Q3 |
| Pentwater Capital Management LP | EXIT | 6,720,000 | 0 | -100.0% | $0.00 | 2025-Q3 |
| FARALLON CAPITAL MANAGEMENT LLC | EXIT | 3,612,000 | 0 | -100.0% | $0.00 | 2025-Q3 |
| BAKER BROS. ADVISORS LP | EXIT | 1,691,530 | 0 | -100.0% | $0.00 | 2025-Q3 |
| VANGUARD GROUP INC | EXIT | 4,191,854 | 0 | -100.0% | $0.00 | 2025-Q3 |
| Pentwater Capital Management LP | NEW | — | 6,720,000 | — | $75.5M | 2025-Q2 |
| FARALLON CAPITAL MANAGEMENT LLC | DOUBLED | 912,000 | 3,612,000 | +296.1% | $40.6M | 2025-Q2 |
| UBS Group AG | DOUBLED | 131,773 | 1,870,522 | +1319.5% | $21.0M | 2025-Q2 |
| Hudson Bay Capital Management LP | NEW | — | 1,747,598 | — | $19.6M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 180,800 | 1,047,600 | +479.4% | $11.8M | 2025-Q2 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 444,509 | 817,532 | +83.9% | $9.2M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 379,581 | 812,360 | +114.0% | $9.1M | 2025-Q2 |
| Trexquant Investment LP | TRIM | 588,417 | 229,781 | -60.9% | $2.6M | 2025-Q2 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | ADD | 133,566 | 183,610 | +37.5% | $2.1M | 2025-Q2 |
| Invesco Ltd. | ADD | 85,360 | 143,445 | +68.0% | $1.6M | 2025-Q2 |
| AMERIPRISE FINANCIAL INC | DOUBLED | 46,448 | 103,955 | +123.8% | $1.2M | 2025-Q2 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | TRIM | 140,727 | 86,613 | -38.5% | $972.9K | 2025-Q2 |
| Rafferty Asset Management, LLC | TRIM | 112,582 | 75,235 | -33.2% | $844.9K | 2025-Q2 |
| STIFEL FINANCIAL CORP | TRIM | 145,377 | 75,059 | -48.4% | $842.9K | 2025-Q2 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 43% buy across 14 analysts — 2 strong buy, 4 buy, 8 hold, 0 sell, 0 strong sell. No current recommendation available.
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Nov 1, 2025 | 2 | 4 | 8 | 0 | 0 | 43% | |
| Oct 1, 2025 | 2 | 4 | 8 | 0 | 0 | 43% | |
| Sep 1, 2025 | 2 | 4 | 8 | 0 | 0 | 43% | |
| Aug 1, 2025 | 2 | 4 | 8 | 0 | 0 | 43% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.